Health Insurance Legislation (Section 3C Pathology – 17p chromosomal deletion testing) Revocation Determination 2023

Administered by Department of Health, Disability and Ageing

Legislation au F2023L01271 Not in force Legislative Instrument

Legislation content

EXPLANATORY STATEMENT

 

Health Insurance Act 1973

Health Insurance Legislation (Section 3C Pathology – 17p chromosomal deletion testing) Revocation Determination 2023

 

Subsection 3C(1) of the Health Insurance Act 1973 (the Act) provides that the Minister may, by legislative instrument, determine that a health service not specified in an item in the pathology services table (the PST) shall, in specified circumstances and for specified statutory provisions, be treated as if it were specified in the PST.  

The PST is set out in the regulations made under subsection 4A of the Act. The most recent version of the regulations is the Health Insurance (Pathology Services Table) Regulations 2020.  

This instrument relies on subsection 33(3) of the Acts Interpretation Act 1901 (AIA).  Subsection 33(3) of the AIA provides that where an Act confers a power to make, grant or issue any instrument of a legislative or administrative character (including rules, regulations or by-laws), the power shall be construed as including a power exercisable in the like manner and subject to the like conditions (if any) to repeal, rescind, revoke, amend, or vary any such instrument.

Purpose

The purpose of the Health Insurance Legislation (Section 3C Pathology – 17p chromosomal deletion testing) Revocation Determination 2023 (the Revocation Determination) is to revoke the Health Insurance (Section 3C Pathology – 17p chromosomal deletion testing) Determination 2023 (the Principal Determination) containing item 73343 which will be incorporated into the PST by the Health Insurance Legislation Amendment (2023 Measures No. 3) Regulations 2023 on 1 November 2023.

The revocation of the Principal Determination is administrative in nature and patients will continue to have access to the Medicare Benefits Schedule (MBS) item listed in the Principal Determination, as the item will be specified in the PST from 1 November 2023.

Consultation

Consultation was not undertaken for this instrument as the revocation of the Principal Determination is machinery in nature and does not alter existing arrangements. There is no change to the arrangements for patients and health professionals, and Medicare will continue to subsidise the service.

The Revocation Determination is a legislative instrument for the purposes of the Legislation Act 2003.

The Revocation Determination commences immediately after the commencement of Schedule 6 of the Health Insurance Legislation Amendment (2023 Measures No. 3) Regulations 2023.

Details of the Revocation Determination are set out in the Attachment.

       

 

Authority:     Subsection 3C(1) of the

 Health Insurance Act 1973

ATTACHMENT

 

Details of the Health Insurance Legislation (Section 3C Pathology – 17p chromosomal deletion testing) Revocation Determination 2023.

 

Section 1 – Name

 

Section 1 provides for the Revocation Determination to be referred to as the Health Insurance Legislation (Section 3C Pathology – 17p chromosomal deletion testing) Revocation Determination 2023 (the Revocation Determination).

 

Section 2 – Commencement

 

Section 2 provides for the Revocation Determination to commence immediately after the commencement of Schedule 6 of the Health Insurance Legislation Amendment (2023 Measures No. 3) Regulations 2023.  

 

Section 3 – Authority

 

Section 3 provides that the Revocation Determination is made under subsection 3C(1) of the Health Insurance Act 1973.

 

Section 4 – Schedules

 

Section 4 provides that the determination made under subsection 3C(1) of the Health Insurance Act 1973 listed in Schedule 1 of the Revocation Determination is revoked.

 

Schedule 1 – Repeals

 

Schedule 1 revokes the whole of the Health Insurance (Section 3C Pathology –17p chromosomal deletion testing) Determination 2023.


Statement of Compatibility with Human Rights

Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011

 

Health Insurance Legislation (Section 3C Pathology – 17p chromosomal deletion testing) Revocation Determination 2023

 

This instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.

Overview of the Determination

The purpose of the Health Insurance Legislation (Section 3C Pathology – 17p chromosomal deletion testing) Revocation Determination 2023 (the Revocation Determination) is to revoke the Health Insurance (Section 3C Pathology – 17p chromosomal deletion testing) Determination 2023 (the Principal Determination) containing item 73343 which will be incorporated into the pathology services table (he PST) by the Health Insurance Legislation Amendment (2023 Measures No. 3) Regulations 2023 on 1 November 2023.

 

The revocation of the Principal Determination is administrative in nature and patients will continue to have access to the Medicare Benefits Schedule (MBS) item listed in the Principal Determination, as the item will be specified in the PST from 1 November 2023.

 

Human rights implications

This instrument engages Articles 9 and 12 of the International Covenant on Economic Social and Cultural Rights (ICESCR), specifically the rights to health and social security.

The Right to Health

The right to the enjoyment of the highest attainable standard of physical and mental health is contained in Article 12(1) of the ICESCR. The UN Committee on Economic Social and Cultural Rights (the Committee) has stated that the right to health is not a right for each individual to be healthy, but is a right to a system of health protection which provides equality of opportunity for people to enjoy the highest attainable level of health.

The Committee reports that the ‘highest attainable standard of health’ takes into account the country’s available resources. This right may be understood as a right of access to a variety of public health and health care facilities, goods, services, programs, and conditions necessary for the realisation of the highest attainable standard of health.

The Right to Social Security

The right to social security is contained in Article 9 of the ICESCR. It requires that a country must, within its maximum available resources, ensure access to a social security scheme that provides a minimum essential level of benefits to all individuals and families that will enable them to acquire at least essential health care. Countries are obliged to demonstrate that every effort has been made to use all resources that are at their disposal in an effort to satisfy, as a matter of priority, this minimum obligation.

The Committee reports that there is a strong presumption that retrogressive measures taken in relation to the right to social security are prohibited under ICESCR. In this context, a retrogressive measure would be one taken without adequate justification that had the effect of reducing existing levels of social security benefits, or of denying benefits to persons or groups previously entitled to them. However, it is legitimate for a Government to re-direct its limited resources in ways that it considers to be more effective at meeting the general health needs of all society, particularly the needs of the more disadvantaged members of society.

The right of equality and non-discrimination

The rights of equality and non-discrimination are contained in articles 2, 16 and 26 of the International Covenant on Civil and Political Rights (ICCPR).  Article 26 of the ICCPR requires that all persons are equal before the law, are entitled without any discrimination to the equal protection of the law and in this respect, the law shall prohibit any discrimination and guarantee to all persons equal and effective protection against discrimination on any ground such as race, colour, sex, language, religion, political or other opinion, national or social origin, property, birth or other status.

Analysis

This instrument does not affect the right to health and social security, and the rights of equality and non-discrimination. This is an administrative consolidation and there is no change to the Medicare arrangements for patients or health providers.

 

Conclusion

This instrument is compatible with human rights as it maintains the right to health and the right to social security and the right of equality and non-discrimination.

 

 

Mary Warner

Assistant Secretary

Diagnostic Imaging and Pathology Branch

Medicare Benefits and Digital Health Division

Health Resourcing Group

Department of Health and Aged Care

Overview

The Health Insurance Legislation (Section 3C Pathology – 17p chromosomal deletion testing) Revocation Determination 2023 was enacted to address an administrative need within the framework of the Health Insurance Act 1973. This Act, enacted in 1973, establishes the legislative foundation for health insurance in Australia, including the administration of the Medicare Benefits Schedule and the Pathology Services Table. The Revocation Determination, made under the authority of subsection 3C(1) of the Health Insurance Act 1973 by the Minister for Health and Aged Care, aims to streamline and update the legislative framework surrounding the provision of pathology services, specifically addressing the treatment of 17p chromosomal deletion testing. The policy objective of this instrument is to ensure that administrative changes do not impact patient access to essential health services, while maintaining the integrity and effectiveness of the Medicare system. The Revocation Determination revokes the Health Insurance (Section 3C Pathology – 17p chromosomal deletion testing) Determination 2023, an administrative action that will not alter the existing arrangements for patients and health professionals. This consolidation is intended to simplify and update the legislative instruments governing pathology services, ensuring that the Pathology Services Table accurately reflects the services covered under Medicare. The determination is compatible with human rights, maintaining the right to health and social security and ensuring equality and non-discrimination, as it does not change the current arrangements for patients or health providers. The Revocation Determination is a legislative instrument under the Legislation Act 2003 and commences immediately after the commencement of Schedule 6 of the Health Insurance Legislation Amendment (2023 Measures No. 3) Regulations 2023.

Scope and Application

The Health Insurance Legislation (Section 3C Pathology – 17p chromosomal deletion testing) Revocation Determination 2023 applies to the revocation of the Health Insurance (Section 3C Pathology – 17p chromosomal deletion testing) Determination 2023. This instrument operates within the framework of the Health Insurance Act 1973, specifically under subsection 3C(1), which empowers the Minister to determine that certain health services not specified in the pathology services table (PST) should be treated as if they were specified. The Revocation Determination is a legislative instrument, effective from the moment it is made, and serves to streamline administrative processes without altering existing healthcare provisions for patients or health professionals. It is designed to ensure that patients continue to have access to the Medicare Benefits Schedule (MBS) item, which will be specified in the PST from 1 November 2023. The Revocation Determination does not involve any consultation as it is considered a machinery change that does not affect the existing arrangements, thereby maintaining the continuity of healthcare services. The scope of this legislation is limited to the administrative aspects of health service specifications within the Medicare framework. It does not extend to altering the rights to health and social security or affect the principles of equality and non-discrimination. Instead, it ensures a seamless transition of a specific pathology test into the PST, thereby maintaining the integrity of the healthcare system while avoiding any potential retrogressive measures that might undermine the rights guaranteed under the International Covenant on Economic, Social and Cultural Rights (ICESCR) and the International Covenant on Civil and Political Rights (ICCPR).

Key Provisions

The Health Insurance Legislation (Section 3C Pathology – 17p chromosomal deletion testing) Revocation Determination 2023 (the Revocation Determination) provides the legal framework for revoking the Health Insurance (Section 3C Pathology – 17p chromosomal deletion testing) Determination 2023 (the Principal Determination) which included item 73343. This item is scheduled to be incorporated into the pathology services table (PST) via the Health Insurance Legislation Amendment (2023 Measures No. 3) Regulations 2023 on 1 November 2023 (Section 4). The Revocation Determination itself is made under subsection 3C(1) of the Health Insurance Act 1973 and it comes into effect immediately after the commencement of Schedule 6 of the Health Insurance Legislation Amendment (2023 Measures No. 3) Regulations 2023 (Section 2, 3). The Revocation Determination places specific obligations on the relevant parties by revoking the Principal Determination administratively. This ensures that the item in question, which provides for 17p chromosomal deletion testing, will still be available under the Medicare Benefits Schedule (MBS) as it will be specified in the PST from 1 November 2023. The revocation does not alter existing arrangements, meaning that patients will continue to have access to this pathology service without interruption. Health professionals and patients alike will experience no changes in the current Medicare arrangements as a result of this legislative instrument. Under the Revocation Determination, there are no direct criminal or civil penalties for non-compliance as this instrument primarily serves an administrative function. However, the broader legislative framework provided by the Health Insurance Act 1973 and associated regulations do contain provisions for offences and penalties related to the provision of health services. For instance, section 103 of the Health Insurance Act 1973 provides for penalties for false or misleading statements related to health services, with potential fines up to $22,200 for individuals and $111,000 for corporations. Additionally, section 105 of the Act imposes penalties for other breaches, which can include fines and imprisonment. These provisions ensure compliance with Medicare regulations and the integrity of the health insurance system. In summary, the Health Insurance Legislation (Section 3C Pathology – 17p chromosomal deletion testing) Revocation Determination 2023 serves to administratively revoke the Principal Determination while ensuring continuity of access to the specified pathology service under the MBS. The determination does not impose new obligations on patients or health professionals beyond what is already established under the existing legislative framework. While the Revocation Determination itself does not carry specific penalties for non-compliance, the overarching legislation provides for significant penalties for broader non-compliance with Medicare regulations.

Legal classification tags

Area of Law
Health Law
Instrument
Legislative Instrument
Concepts
Commencement Provisions
Repeal & Amendment
Regulatory Standards

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.